Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for Preventing or Treating Cervical Cancer Having Human Papillomavirus Plasmodium and Immunity Enhancer

a technology of human papillomavirus and plasmodium plasmodium, which is applied in the direction of viruses, drug compositions, peptides, etc., can solve the problems of poor therapeutic effect of composition, and achieve the effect of improving immunogenicity

Active Publication Date: 2013-08-01
GENEXINE INC
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention introduces a new fusion protein that can prevent or treat diseases caused by the Human Papillomavirus (HPV). This protein is designed to stop the HPV E6 and E7 proteins from becoming cancer. Additionally, the fusion protein is more effective in stimulating the immune system. The patent text also includes a polynucleotide that encodes this fusion protein.

Problems solved by technology

In clinical trials using a composition including a nucleic acid sequence in which HPV16 E6 and E7 proteins are simultaneously expressed to treat cervical cancer, however, the composition has shown a poor therapeutic effect (Garcia F et al.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for Preventing or Treating Cervical Cancer Having Human Papillomavirus Plasmodium and Immunity Enhancer
  • Composition for Preventing or Treating Cervical Cancer Having Human Papillomavirus Plasmodium and Immunity Enhancer
  • Composition for Preventing or Treating Cervical Cancer Having Human Papillomavirus Plasmodium and Immunity Enhancer

Examples

Experimental program
Comparison scheme
Effect test

example 1

Construction of GX-188E DNA

[0068]Abbreviations used in the Examples of the present invention are defined as follows. An optimized nucleic acid sequence, “tPa” or “t” refers to a secretory signal sequence of a tissue plasminogen activator, and “F” or “Flt3L” refers to an fms-like tyrosine kinase-3 ligand.

[0069]A codon-optimized tPa secretory signal sequence having a nucleic acid sequence set forth in SEQ ID NO: 5 and a codon-optimized Flt3L having a nucleic acid sequence set forth in SEQ ID NO: 6 were chemically synthesized while the codon-optimized tPa and Flt3L secretory signal sequences were coupled to each other. A terminus of the synthesized signal sequence was provided with KpnI (5′) and NheI (3′) restriction sites to facilitate insertion into a vector. A vector for preparing a DNA vaccine, that is, pGX10 (Korean Patent Publication No. 2003-0047667) was digested with KpnI and NheI restriction enzymes, and then ligated with the synthesized tPa-Flt3L signal sequence using ligase ...

example 2

Confirmation of Therapeutic Effect of GX-188E on Cervical Cancer

[0071]To confirm a therapeutic effect of GX-188E on cervical cancer, TC-1 tumor cells were subcutaneously injected into C57BL / 6 rats at a concentration of 5×105 cells, and GX-188E was intramuscularly injected at doses of 50 μg and 100 μg on days 3 and 8, followed by performing electroporation. A change in volume of tumor cells was observed from the day of injection to day 27, and the spleens of the rats were extracted on Day 36. Then, 1×106 cells were put into a plate coated with 50 μl of a 5 μg / ml anti-mouse IFN-g antibody (BD Pharmigen, San Diego, Calif.) together with IL-2 and an HPV16 E6 CD8 T cell epitope (E648-57; EVYDFAFRDL, Peptron, Korea), an HPV18 E7 CD8 T cell epitope (E749-57; RAHYNIVTF, Peptron, Korea), an HPV18 E6 peptide pool, or an HPV18 E7 peptide pool, and incubated at 37° C. for 24 hours in a 5% CO2 incubator (Froma, Minn., USA). The plate was washed with PBST, and a 2 μg / ml IFN-g detection antibody c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
3D) structureaaaaaaaaaa
3D structureaaaaaaaaaa
expression frequencyaaaaaaaaaa
Login to View More

Abstract

A composition for preventing or treating cervical cancer comprising a human papillomavirus plasmodium and an immunity enhancer is provided. A fusion protein including a fusion polypeptide recombined to transform a 3D structure of E6 and E7, which are antigens against types 16 and 18 human papillomavirus (HPV), a signal peptide for secreting the fusion polypeptide outside the cells and an immunity enhancer peptide present in an individual is also provided. The fusion protein may be useful in treating HPV-triggered tumors by inducing an immune response specific to the antigens against the HPV types 16 and 18.

Description

BACKGROUND[0001]1. Field of the Invention[0002]The present invention relates to a composition for preventing or treating cervical cancer comprising a human papillomavirus (HPV) plasmodium and an immunity enhancer, and, more particularly, to a fusion protein including a fusion polypeptide recombined to transform a 3-dimensional (3D) structure of E6 and E7, which are antigens of types 16 and 18 HPV, a signal peptide for secreting the fusion polypeptide outside the cells, and an immunity enhancer peptide present in an individual, wherein the fusion protein may treat HPV-triggered tumors by inducing an immune response specific to HPV type 16 and 18 antigens.[0003]2. Discussion of Related Art[0004]Cervical cancer has been known as a disease that develops from infection of human papillomaviruses (HPVs) of very high concern such as types 16 and 18 (zur Hausen, H et al. Biochem Biophys Acta 1996, 1288; F55-F78, Mark H et al. J Natl Cancer Inst 1993, 85; 958-964). Among HPV proteins, E6 and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K14/01
CPCC07K2319/00C07K2319/036C12N15/62C07K14/005C12N2710/20022C07K14/01C12N2710/20034A61P15/00A61P15/02A61P31/20A61P35/00Y02A50/30A61K39/12C07K2319/02C12N7/00
Inventor SUNG, YOUNG CHULSEO, SANG HWANSUH, YOU SUK
Owner GENEXINE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com